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Background: It has been reported that the PI3K/AKT signaling pathway is activated in diffuse large B-cell lymphoma
(DLBCL), PI3K constitutive activation plays a crucial role in PI3K/AKT pathway. However, the copy number variations
(CNVs) of PI3K subunits on gene level remain unknown in DLBCL. Therefore, the aim of the study is to investigate the
CNV of PI3K subunits and their relationship with clinicopathological features exploring the possible mechanism
underlying of PI3K activation in DLBCL.
Methods: CNV of 12 genes in the PI3K/AKT pathway was detected by NanoString nCounter in 60 de novo DLBCLs
and 10 reactive hyperplasia specimens as controls. Meanwhile, immunohistochemistry (IHC) was performed to
examine the expression of p110α, p110β, p110γ, p110δ, and pAKT on DLBCL tissue microarrays.
Results: All PI3K and AKT subunits, except for PIK3R1, had various CNVs in the form of copy number amplifications
and copy number losses. Their rates were in the range of 8.3–20.0%. Of them PIK3CA and PIK3CB gene CNVs were
significantly associated with decreased overall survival (P = 0.029 and P = 0.019, respectively). IHC showed that the
frequency of strong positive expression of p110α, p110β, p110γ, and p110δ were 26.7%, 25.0%, 18.3%, and 25.0%
respectively, and they were found to be associated with decreased survival (P = 0.022, P = 0.015, P = 0.015, and
P = 0.008, respectively). Expression of p110α was not only significantly associated with CNVs of PIK3CA (P = 0.002)
but also positively correlated with strong positive expression of pAKT (P = 0.026).
Conclusions: CNV of PIK3CA is highly associated with aberrant p110α protein expression and subsequent activation of
PI3K/AKT pathway. CNVs of PIK3CA and PIK3CB, and aberrant protein expression of p110 isoforms are of great important
value for predicting inferior prognosis in DLBCL. Frequent CNVs of PI3K/AKT subunits may play an important role in the
tumorigenesis of DLBCL.
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Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon non-Hodgkin’s lymphoma, accounting for 30–40% of
adult non-Hodgkin’s malignant lymphoma [1]. Although
patients diagnosed with DLBCL are potentially curable
with chemotherapy, the disease proves to be fatal in ap-
proximately 50% of patients [2]. Recently, given that there
has been an increasing trend in the incidence of DLBCL,
it is imperative to develop specific and effective treatments
related to the pathogenesis of the disease.
Previous studies have reported that the phosphatidyli-
nositol 3-kinase (PI3K) signaling pathway plays a critical
role in regulating the growth and survival of DLBCL
cells [3], and that constitutive phosphorylation of PI3K
resulted in the activation of signaling that represented
frequent events both for main pathway components and
their downstream substrates [4]. Activated PI3K/AKT
signaling pathways have been reported to be associated
with decreased disease-free survival (DFS) and a poor
response to treatment in patients with DLBCL [5]. This
suggests that the PI3K/AKT pathway is potentially an
important tumorigenic signaling route and an unfavor-
able prognostic factor in DLBCL.
PI3Ks consist of a large and complex family that con-
tains three classes, I, II, and III. Of them, Class I PI3K is
the most studied and plays a key role in the develop-
ment and progression of tumors [6]. Class I contains the
class IA catalytic subunits PIK3CA, PIK3CB, PIK3CD,
and class IB catalytic subunit PIK3CG and the regulatory
subunits PIK3R1, PIK3R2, and PIK3R3, while class II
contains the catalytic subunits PIK3C2A, PIK3C2B, and
PIK3C2G [4]. However, how each subunit precisely con-
tributes to the progression and maintenance of tumors
is largely undetermined. The PI3K/AKT signaling pathway
can be activated by two main mechanisms: activating
mutations and amplifications [7]. Amplification of genes
encoding the catalytic subunits of PIK3CA, PIK3CB,
PIK3CD, and PIK3CG has been reported in numerous
solid tumors [7]. In lymphomas, PIK3CA has been re-
ported to be amplified in 15/22 (68%) cases of mantle
cell lymphoma (MCL) [8], 9/161 (5.6%) cases of chronic
lymphocytic leukemia (CLL) [9], and mutated in 1/76
(1.3%) cases of DLBCL [10]; while PIK3CD has been re-
ported to be mutated in 3/73 (4.1%) cases of DLBCL
[11]. However, there have been few reports available
regarding CNVs or mutations of other PI3K/AKT sub-
units and their contribution to the activation of the
PI3K/AKT pathway in DLBCL.
In the present study, we focused mainly on the various
PI3K/AKT subunits and profiled their CNVs using the
NanoString nCounter assay and investigated their pro-
tein expression by immunohistochemistry (IHC). Fur-
thermore, we analyzed the association of CNVs and
protein expression with clinicopathological parametersin DLBCL. We also studied various members of the
PI3K/AKT pathway simultaneously in the same set of
DLBCL clinical samples as well as in a panel of lymph-
oma cell lines to investigate their involvement in the
pathogenesis of DLBCL.
Materials and methods
Tissue specimens, cell lines, and patient information
A total of 70 fresh frozen samples including 60 DLBCLs
and 10 lymph node reactive hyperplasias (RHs) were
collected for CNV detection on the NanoString nCoun-
ter platform (NanoString Technologies, Seattle, WA,
USA). DLBCL cell lines (DOHH2, OCI-Ly1, OCI-Ly8,
and Toledo) and Burkitt’s lymphoma (BL) cell lines
(Raji, Namalwa) were included. Corresponding DLBCL
formalin-fixed, paraffin-embedded (FFPE) tissues were
collected for IHC detection of PI3K catalytic subunits.
All cases used in the present study were retrieved dur-
ing an 8-year period (2005–2012) from our tumor bank
and the Department of Pathology in the Shanghai
Cancer Center. Diagnoses were reviewed by two pathol-
ogists (Wenli Cui and Ying Cai) based on the 2010
World Health Organization classification. The other
relevant clinical pathological information including
primary site, B symptoms, bulky disease, performance
status, lactate dehydrogenase (LDH) activity, stage,
International Prognostic Index (IPI) were collected.
The DLBCLs were classified into GCB and non-GCB
subtype according to Hans algorithm [12]. 13/60 (22%) pa-
tients received R-CHOP (Rituximab, cyclophosphamide,
doxorubicin, vincristine, and prednisone) or R-CHOP-like
therapy, and 47/60 (78%) patients received CHOP or
CHOP-like therapy. Patient clinical information was ex-
tracted from hospital records. Research protocols for this
study were approved by the Ethics Committee at Fudan
University Shanghai Cancer Center (Shanghai, China).
NanoString nCounter assay
Genomic DNA from fresh frozen tissue and cultured cell
lines was extracted using a DNA extraction kit (Qiagen,
Venlo, Netherlands) following the manufacturer’s pro-
tocol. Only DNA samples with an OD A260/280 ratio
between 1.7 and 1.9, which indicates optimal purity for
DNA, were used for further study. For detection of
CNVs in the PI3K/AKT pathway, a panel of custom-
compiled gene probes related to the pathway, including
PI3K catalytic subunits PIK3CA, PIK3CB, PIK3CD,
PIK3CG, PIK3C2A, PIK3C2B, and PIK3C2G, and re-
gulated subunits PIK3R1 and PIK3R2, as well as AKT
subunits AKT1, AKT2, and AKT3 were designed using
NanoString nCounter technology and subsequently ana-
lyzed on the NanoString nCounter platform. NanoString
probes were designed for the 12 genes according to dif-
ferent exons located in different regions (Table 1). Three
Table 1 PI3K/AKT subunits, their localization and exons
for probes
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tained six positive dsDNA control probes, eight negative
control probes, and 10 invariant control probes (INVs)
designed for autosomal genomic regions predicted not
to contain common CNVs.
The NanoString nCounter assay was performed accord-
ing to NanoString’s standard protocol. Briefly, 600 ng of
fragmented genomic DNA per assay was hybridized with
the capture and reporter probes in 30 μL total volume and
incubated overnight at 65°C for at least 16 h. The target
and probe complexes were washed and immobilized in
the cartridge. Genomic DNA was fragmented into small
pieces (200–800 bp) and denatured to produce single
strands. The custom CNV CodeSet was then hybridized
to the fragmented denatured DNA sample in a single mul-
tiplexed reaction (up to 800 genomic loci per CodeSet).
Hybridized DNA-CodeSet complexes were purified using
the fully automated nCounter prep station, and reporters
were counted using the nCounter digital analyzer. The
data were normalized to the INVs and to positive and
negative controls in each hybridization reaction. Finally,
data analysis was performed using nSolver software.
Copy number was determined by averaging over three
probes per region. If the average copy number was below
1.4, the gene was considered as one copy; if between 1.5
and 2.4, considered as two copies; and if between 2.5 and
3.4, considered as three copies, according to the manufac-
turer’s protocol.
Immunohistochemistry
IHC was performed to detect expression of the four PI3K
catalytic isoforms and pAKT on routinely processed FFPE
specimens from which tissue microarrays (TMAs) were
constructed using double cores (core diameter was 1 mm)
from selected areas of 60 cases of DLBCL and 10 cases
of RH. Briefly, serial sections from FFPE samples werecollected onto poly-L-lysine coated slides and processed
with a standard manual streptavidin-peroxidase technique
using a biotin-free detection system (Dako, Carpinteria,
CA, USA) after a heat-induced antigen retrieval procedure
with EDTA for pAKT and citric acid for other antigens for
3 min. Primary antibodies were incubated with TMAs
overnight. Omission of the primary antibody and its
replacement with an antibody diluent were used as the
negative control. A ready-to-use kit (EnVision™; Dako)
was used according to the manufacturer’s instructions.
The source and dilution of the primary antibodies
used were as follows: PI3K p110α (#4249, clone C73F8,
1:400), PI3K p110β (#3011, clone C33D4, 1:400), and
PI3K p110γ (#5405, clone D55D5, 1:200) were from Cell
Signaling Technology (Beverly, MA, USA), PI3K p110δ
(sc-7176, clone H-219, 1:200) was from Santa Cruz Bio-
technology (Dallas, TX, USA), and pAKT (Ser 473)
(#2118-1, clone EP2109Y, 1:150) was from Epitomics
(Burlingame, CA, USA).
Scoring of immunostaining
Expression of the four PI3K catalytic isoforms was evalu-
ated blindly and independently by two pathologists
(Wenli Cui and Ying Cai). The staining intensity was
scored from 0 to 3: 0, no appreciable staining in tumor
cells (negative); 1, slight staining in tumor cells (weak posi-
tive); 2: moderate staining in tumor cells (moderate posi-
tive); 3: distinct staining in tumor cells (strong positive)
[5]. Cases were considered positive if ≥30% of the tumor
cells were stained with an antibody, as described in a pre-
vious study involving IHC evaluation of TMAs [12].
Statistical analysis
Overall survival (OS) was measured from date of diag-
nosis to date of death of any cause, or latest follow-up.
Survival analysis was performed using Kaplan–Meier
survival curves with a statistical software package (IBM
SPSS Statistics 20.0, Armonk, Town of North Castle,
NY, USA) and compared with the use of logistic statis-
tics (log-rank). The Fisher’s exact or χ2 test was used for
statistical analysis of categorical data. The Cox propor-
tional hazard regression model was used for univariate
analyses. A P-value <0.05 was considered statistically
significant.
Results
CNV of 12 genes in the PI3K/AKT pathway in DLBCL
We analyzed CNVs of 12 genes in a total of 60 DLBCLs,
six cell lines including DOHH2, OCI-Ly1, OCI-Ly8,
Toledo, Raji, and Namalwa, and 10 lymphoid hyperplasias.
The results showed that 11 of the 12 PI3K/AKT family
members had significant CNVs, including copy number
amplifications and copy number losses. These were
PIK3CA (17%), PIK3CB (20%), PIK3CD (17%), PIK3CG
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PIK3R2 (23%), AKT1 (18%), AKT2 (18%), and AKT3
(22%) (Table 2). Among genes with CNVs, we found that
the copy numbers of PIK3CA, PIK3CB, PIK3R2, and
PIK3C2B were only amplified (10/10, 12/12, 14/14, and
8/8, respectively); copy numbers of PIK3CG, PIK3C2A,
PIK3C2G, AKT1, AKT2, and AKT3 were amplified in
the majority of cases (4/5, 4/5, 11/12, 7/11, 8/11, and
11/13, respectively), whereas copy number losses oc-
curred in fewer cases (1/5, 1/5, 1/12, 4/11, 3/11, and
2/13, respectively); copy number losses for PIK3CD oc-
curred in the majority of cases (7/10), whereas amplifi-
cations occurred in a few cases (3/10) (Table 3). In
DLBCL, the CNV frequency of PI3K-AKT subunits was
in the range of 1–10 genes; in one of the 60 DLBCLs, 10
different genes were detected with CNVs. In this sample
set, 58.3% (35/60) of patients had at least one CNV and
48.3% (29/60) had at least two co-occurring CNVs in the
component of PI3K/AKT subunit genes (Table 4). CNVs
were identified in most of the PI3K/AKT family genes in
DLBCL. There was no statistically correlation found be-
tween any CNVs of PI3K gene family and that of AKT
gene family, indicating there was no cause-and-effect
interplay between CNVs of PI3K and AKT.
PIK3CG was found to be amplified in all GCB cell
lines, including DOHH2, OCI-Ly1, OCI-Ly8, and To-
ledo; PIK3C2A and AKT1 were amplified in OCI-Ly1,
OCI-Ly8, and Toledo; while PIK3C2B and PIK3C2G
were amplified only in Toledo (Table 5).
Protein expression of PI3K catalytic subunits in DLBCL
To further investigate the association between CNVs of
PI3K subunits and their protein expression, and theTable 2 The frequency CNV of PI3K/AKT subunits in 60











PIK3CA 60 10 (17) 0 (0) 10 (17)
PIK3CB 60 12 (20) 0 (0) 12 (20)
PIK3CD 60 3 (5) 7 (12) 10 (17)
PIK3CG 60 4 (6) 1 (2) 5 (8)
PIK3R1 60 0 (0) 0 (0) 0 (0)
PIK3R2 60 14 (23) 0 (0) 14 (23)
PIK3C2A 60 4 (6) 1 (2) 5 (8)
PIK3C2B 60 8 (13) 0 (0) 8 (13)
PIK3C2G 60 11 (18) 1 (2) 12 (20)
AKT1 60 7 (12) 4 (6) 11 (18)
AKT2 60 8 (13) 3 (5) 11 (18)
AKT3 60 11 (18) 2 (3) 13 (22)significance of Class I subunits in DLBCL, we analyzed
the expression of p110α, p110β, p110γ, p110δ, and
pAKT protein in a TMA of 60 DLBCLs using IHC. All
of these proteins were expressed in the cytoplasm. In
DLBCL, proteins were diffusely expressed in tumor
cells, while in RH they were locally expressed in germi-
nal centers (Figure 1). The expression frequencies of
p110α, p110β, p110γ, p110δ, and pAKT protein were
80%, 81.6%, 81.6%, 81.6%, and 75%, respectively. Strong
positive expression of the above proteins was found in
26.7%, 25.0%, 25.0%, 18.3%, and 16.7% of cases, respect-
ively. Among the four PI3K subunit proteins expressed,
only p110α showed strong positive expression, which
was positively correlated with CNVs of PIK3CA (P =
0.002). P110α strong positive expression was also corre-
lated with strong positive expression of pAKT (P =
0.026). Other strong positive expressions of p110β,
p110γ, and p110δ have no correlation with CNVs of
PIK3CB, PIK3CG and PIK3CD. There was no signifi-
cant correlation between the expression of these p110
isoforms and expression of pAKT.
Association between CNVs in PI3K/AKT genes and
clinicopathological characteristics in DLBCL
Among the 60 patients with DLBCLs, their ages were in
the range of 21–86 years with a mean age of 58 years.
Fifty-seven cases had follow-up data from 2 to 79 months,
with the average period being 34 months. During this
period, 15/57 (26%) patients died. There was a significant
association of shorter survival with CNVs of PIK3CA and
PIK3CB (Figure 2). Patients with CNVs of PIK3CA and
PIK3CB had significantly shorter survival times respect-
ively (P = 0.029, n = 10; P = 0.019, n = 12) than those with
two wild-type copies (Figure 2A, Figure 2B). Patients
whose DLBCLs had either PIK3CA or PIK3CB CNVs had
significantly shorter survival times (P = 0.007, n = 13) than
those without CNVs (Figure 2E). Both PIK3CA and
PIK3CB CNVs had no significant shorter survival times
(P = 0.069, n = 8) than those without CNVs (Figure 2F).
No significant differences or similarities in survival were
seen for patients with CNVs of PIK3CD (Figure 2C),
PIK3CG (Figure 2D), PIK3C2A, PIK3C2B, PIK3C2G,
PIK3R2, AKT1, AKT2, or AKT3. CNVs of PIK3CA and
PIK3CB were higher in the non-GCB DLBCLs (n = 8
and n = 10, respectively) than in the GCB DLBCLs (n = 2
and n = 2, respectively). No difference in different patho-
logical types was seen in other subunits. There were no
significant differences between CNVs of PIK3CA, PIK3CB,
PIK3CD, and PIK3CG with clinicopathological character-
istics, including sex, age, primary site, B symptoms, bulky
disease, performance status, LDH activity, stage, IPI, or
pathological type (Table 6). Clinicopathological character-
istics had no impact on survival through Cox regression
univariate analysis.
Table 3 The distribution of varied CNV in each PI3K/AKT subunits by NanoString nCounter analysis
Gene Total CNV no. Copy number loss no. (%) Copy number amplification no. (%) Total copy number
amplification no. (%)1 copy 3 copy 4 copy 6 copy
PIK3CA 10 0 (0) 9 (90) 1 (10) 0 (0) 10 (100)
PIK3CB 12 0 (0) 11 (92) 1 (8) 0 (0) 12 (100)
PIK3CD 10 7 (70) 2 (20) 1 (10) 0 (0) 0 (30)
PIK3CG 5 1 (20) 4 (80) 0 (0) 0 (0) 4 (80)
PIK3R1 0 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
PIK3R2 14 0 (0) 12 (86) 1 (7) 1 (7) 14 (100)
PIK3C2A 5 1 (20) 4 (80) 0 (0) 0 (0) 4 (80)
PIK3C2B 8 0 (0) 8 (100) 0 (0) 0 (0) 8 (100)
PIK3C2G 12 1 (8) 10 (84) 1 (8) 0 (0) 11 (92)
AKT1 11 4 (36) 6 (55) 1 (9) 0 (0) 7 (64)
AKT2 11 3 (27) 8 (73) 0 (0) 0 (0) 8 (73)
AKT3 13 2 (15) 9 (69) 2 (16) 0 (0) 11 (85)
Table 5 Copy number of PI3K/AKT pathway in DLBCLs
and BLs cell lines
DLBCL BL
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There were no positive correlations between strong posi-
tive expression of p110α, p110β, p110γ, and p110δ with
clinicopathological characteristics, including sex, age,
primary site, B symptoms, bulky disease, performance
status, LDH activity, stage, IPI, and pathological type, ex-
cept for p110δ, which had a significant difference in high
IPI (P = 0.037) (Table 7). Strong positive expression of
p110α, p110β, p110γ, and p110δ was found to be as-
sociated with decreased survival (P = 0.022, P = 0.015,
P = 0.015, and P = 0.008 respectively) (Figure 3A, 3B,
3C, 3D). Strong and moderate expression of pAKT asso-
ciated with decreased survival (P = 0.165) (Figure 3E).
Discussion
Given the important involvement of the PI3K/AKT
pathway in the pathogenesis of tumors, and given the
paucity of datas regarding CNV in PI3K/AKT gene
members in DLBCL, we first investigated CNVs usingTable 4 CNV of PI3K/AKT subunits genes involved in 60
DLBCLs
Genes involoved (≥) Total case no. CNV no. Frequency
PI3K/AKT
subunits
1 genes 60 35 58%
2 genes 60 29 48%
3 genes 60 25 42%
4 genes 60 18 30%
5 genes 60 12 20%
6 genes 60 6 10%
7 genes 60 3 5%
9 genes 60 2 3%
10 genes 60 1 2%NanoString nCounter’s method [13] in 12 members of
the PI3K/AKT signaling pathway in human DLBCL
using an nCounter CNV assay. It was found that all
PI3K and AKT subunits besides PIK3R1 had CNVs to a
different extent, generally, with the frequency ranging
from 8.3% to 23%. Among which, CNVs of PIK3CA and
PIK3CB were significantly associated with inferior over-
all survival. Additionally, protein expression of p110α,
p110β, p110γ, and p110δ using IHC method were also
found to be associated with decreased survival.
CNVs have been found in some genes that are compo-
nents of the PI3K/AKT pathway in various tumors
[14-16]. However, little has been reported about CNVs
of the PI3K/AKT in DLBCL. Here we have for the first
time detected CNVs in almost all members of the PI3K/DOHH2 OCI-LY1 OCI-LY8 Toledo Raji Namalwa
PIK3CA 2 2 2 2 2 2
PIK3CB 2 2 2 2 2 2
PIK3CD 2 2 2 2 2 2
PIK3CG 3 3 3 3 2 2
PIK3R1 2 2 2 2 2 2
PIK3R2 2 2 2 2 2 2
PIK3C2A 2 3 3 3 2 2
PIK3C2B 2 2 2 3 2 2
PIK3C2G 2 2 2 3 2 2
AKT1 2 3 3 3 2 2
AKT2 2 2 2 2 2 2
AKT3 2 2 2 4 2 2
Figure 1 (See legend on next page.)
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Figure 1 Protein expression of p110α, p110β, p110γ, p110δ, and pAKT was performed on tissue microarrays by Immunohistochemistry (IHC).
A-C. Weak positive of germinal center in RH, weak positive and strong positive of p110α in DLBCL D-F. Weak positive of germinal center in RH, weak
positive and strong positive of p110β in DLBCL G-I. Weak positive of germinal center in RH, weak positive and strong positive of p110γ in DLBCL J-L. Weak
positive of germinal center in RH, weak positive and strong positive of p110δ in DLBCL M-O. Weak positive of germinal center in RH, weak positive and
strong positive of pAKT in DLBCL.
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CNVs profiles and genetic abnormality as common
event in the PI3K/AKT signaling pathway in DLBCL,
providing evidence and possible explanation for the
pathogenesis of DLBCL on genetic level.
There have been reports showed that PIK3CA gene
was happened to CNVs in ovarian cancer [17], cervical
cancer [18], and gastric cancer [19]; and that CNVs in
PIK3CA were reported to be an independent factor for
predicting poor OS of patients with ovarian cancers [17]
and gastric cancers [19]. Our result showed that each
CNVs of PIK3CA and PIK3CB has significant shorter
survival. Either CNVs of PIK3CA or PIK3CB had signifi-
cant shorter survival too, indicating either PIK3CA or
PIK3CB has significant effects on overall survival. BothFigure 2 Correlation of CNVs of PIK3CA, PIK3CB, PIK3CD, PIK3CG by N
CNV of PIK3CA, PIK3CB were associated with decreased survival. Other PI3K
PIK3CA CNV(P = 0.029). B. Patients grouped by PIK3CB CNV(P =0.019). C. Pa
PIK3CG CNV(P =0.874). E. Patients grouped by either PIKCA or PIK3CB CNV(P =CNVs of PIK3CA and PIK3CB had the effect trend on
survival effect, there was no statistically significance.
In an earlier study, the authors discovered that amplifi-
cation of PIK3CD was significantly higher in patients
who were sensitive to rituximab than that in patients
who were resistant to rituximab [20], suggesting that
CNVs of PIK3CD may be a useful marker used for
chemotherapy sensitivity when selecting the appropriate
chemotherapeutic treatment for patients with DLBCL.
Alizadeh et al. found that PIK3CG was highly expressed
in GCB (germinal center B-cell like), and patients with
GCB DLBCL had a significantly better OS than those
with ABC (activated B-cell like) DLBCL [21], which was
consistent with our detection that PIK3CG expression
was significantly higher in GCB cell lines (n = 4).anoString nCounter analysis with DLBCL survival. It showed that
/AKT subunits represented no correlation. A. Patients grouped by
tients grouped by PIK3CD CNV(P =0.778). D. Patients grouped by
0.007). F. Patients grouped by both PIKCA and PIK3CB CNV(P =0.069).
Table 6 CNV of PI3K subunits in 60 patients with DLBCLs by Nanostring nCounter analysis
PIK3CA P value PIK3CB P value PIK3CD P value PIK3CG P value
Total no. of patients 60
Sex
Male 39 5 (12.8) 0.298 7 (17.9) 0.737 10 (25.6) 0.011 5 (12.8) 0.412
Female 21 5 (23.8) 5 (23.8) 0 (0) 1 (4.8)
Age, years
<60 y 36 6 (16.7) 1.000 5 (13.9) 0.193 6 (16.7) 1.000 5 (13.9) 0.387
≥60 y 24 4 (16.7) 7 (29.2) 4 (16.7) 1 (4.2)
Primary site
node 54 10 (18.5) 0.557 11 (20.4) 1.000 9 (16.7) 1.000 6 (11.1) 1.000
Perpheral node 6 0 (0) 1 (16.7) 1 (16.7) 0 (0.0)
B symptoms
Absence 37 7 (18.9) 0.727 7 (18.9) 1.000 6 (16.2) 1.000 2 (5.4) 0.191
Presence 23 3 (13.0) 5 (21.7) 4 (17.4) 4 (17.4)
Bulky disease
<10 cm 47 7 (14.9) 0.506 8 (17.0) 0.552 7 (14.9) 1.000 4 (8.5) 0.347
≥10 cm 4 1 (25.0) 1 (25.0) 0 (0) 1 (25.0)
Performance status
ECOG 0-1 50 8 (16.0) 1.000 8 (16.0) 1.000 7 (14.0) 0.125 6 (12.0) 1.000
ECOG 2-4 4 0 (0.0) 1 (25.0) 2 (50.0) 0 (0)
LDH
<2*insitutioal ULN 30 6 (34.9) 0.715 6 (20.0) 1.000 6 (20.0) 0.117 3 (10.0) 1.000
>2*insitutioal ULN 24 3 (12.5) 5 (20.8) 1 (4.2) 3 (12.5)
Extranodal site
≤1 50 9 (18.0) 1.000 11 (22.0) 0.571 7 (14.0) 1.000 6 (12.0) 1.000
>1 4 0 (0) 0 (0.0) 0 (0) 0/4 (0)
Stage
I/II 29 3 (10.3) 0.161 3 (10.3) 0.087 4 (13.8) 1.000 1 (3.4) 0.076
III/IV 23 6 (26.1) 7 (30.4) 3 (13.0) 5 (21.7)
IPI
0-1 30 5 (16.7) 1.000 4 (13.3) 0.198 4 (13.3) 1.000 4 (13.3) 0.678
2-5 25 4 (16.0) 7 (28.0) 4 (16.0) 2 (8.0)
Pathology
GCB 26 2 (76.9) 0.163 3 (11.5) 0.152 5 (19.2) 0.733 3 (11.5) 1.000
non-GCB 34 8 (23.5) 9 (26.5) 5 (14.7) 3 (8.8)
DLBCL diffuse large B-cell lymphoma, GCB germinal center B cell, IPI international prognostic index, LDH lactate dehydrogenase.
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of PIK3CA and PIK3CB were positively and significantly
associated with prognosis compared with other members.
Depending on previous research, non-GCB represented
poor overall survival than GCB. Although CNVs of
PIK3CA and PIK3CB were apparently higher in non-GCB
group (80% (8/10) and 67% (8/12), respectively) than that
in GCB group, there was no statistically significant. Copy
number amplification of either PIK3CA or PIK3CB lo-
cated in the same region (3q) showed a correlation withpoor survival in DLBCL patients, indicating that this re-
gion of amplification has significant correlation with sur-
vival in DLBCL. There was no significant correlation
between the CNV and protein level other than PIK3CA,
indicating that CNV of these genes might partially con-
tribute to the aberrant expression of PI3K isoforms sup-
posedly. The inconsistency we discovered here is highly
similar to an earlier report by Ye ZQ and colleagues whose
finding is that there was inconsistency between CNV and
protein differential expression for the most genes [22].
Table 7 Strong positive expresssion of p110 isforms and pAKT in 60 patients with DLBCLs by IHC
p110α P value p110β P value p110δ P value p110γ P value pAKT P value
Total no. of patients 60
Age, years
<60 y 36 12 (33.3) 0.037 10 (27.8) 0.639 12 (33.3) 0.068 7 (19.4) 1.000 7 (19) 0.293
≥60 y 24 4 (16.7) 5 (20.8) 3 (12.5) 4 (16.7) 2 (8.3)
Sex
Male 39 7 (17.9) 0.153 9 (23.1) 0.762 11 (28.2) 0.435 7 (17.9) 1.000 7 (17.9) 0.473
Female 21 9 (42.9) 6 (28.6) 4 (19.0) 4 (19.0) 2 (9.5)
Primary site
node 54 14 (25.9) 0.653 14 (25.9) 1.000 14 (25.9) 1.000 8 (14.8) 0.069 8 (14.8) 1.000
Perpheral node 6 2 (33.3) 1 (26.7) 1 (16.7) 3 (50.0) 1 (16.6)
B symptoms
Absence 37 10 (27.0) 0.936 10 (27.0) 0.764 11 (29.7) 0.283 6 (16.2) 0.734 4 (10.8) 0.284
Presence 23 6 (26.1) 5 (21.7) 4 (17.4) 5 (21.7) 5 (21.7)
Bulky disease
<10 cm 47 11 (23.4) 1.000 13 (27.7) 0.561 12 (25.5) 1.000 8 (17.0) 0.552 7 (14.9) 1.000
≥10 cm 4 1 (25.0) 1 (0) 1 (25.0) 1 (25.0) 0 (0)
Performance status
ECOG 0-1 50 13 (26.0) 1.000 13 (26.0) 0.965 12 (24.0) 1.000 9 (18.0) 0.571 8 (16) 1.000
ECOG 2-4 4 1 (25.0) 1 (25.0) 1 (25.0) 1 (25.0) 0 (0)
LDH
<2*insitutioal ULN 30 9 (30.0) 0.445 11 (36.7) 0.133 9 (30.0) 0.445 7 (23.3) 0.483 6 (20) 0.277
>2*insitutioal ULN 24 5 (20.8) 4 (16.7) 5 (20.8) 3 (12.5) 2 (8.3)
Extranodal site
≤1 50 13 (26.0) 1.000 14 (28.0) 1.000 13 (26.0) 1.000 9 (18.0) 0.571 8 (16) 1.000
>1 4 1 (25.0) 1 (25.0) 1 (25.0) 1 (25.0) 0 (0)
Stage
I/II 29 5 (17.2) 0.077 8 (27.6) 0.904 10 (34.5) 0.168 4 (13.8) 0.307 4 (13.8) 1.000
III/IV 23 9 (39.1) 6 (26.1) 4 (17.4) 6 (26.1) 4 (17.4)
IPI
0-1 30 10 (33.3) 0.142 11 (36.7) 0.087 11 (36.7) 0.037 5 (16.7) 1.000 6 (20) 0.269
2-5 25 4 (16.0) 4 (16.0) 3 (12.0) 5 (20.0) 2 (8)
Pathological type
GCB 26 4 (15.4) 0.084 6 (23.1) 0.764 4 (15.4) 0.133 3 (11.5) 0.320 4 (15.4) 1.000
non-GCB 34 12 (35.3) 9 (26.5) 11 (32.4) 8 (23.5) 5 (14.7)
DLBCL diffuse large B-cell lymphoma, GCB germinal center B cell, IPI international prognostic index, LDH lactate dehydrogenase.
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http://www.translational-medicine.com/content/12/1/10In our present study, not only were CNVs detected in
clinical sample of DLBCL, but also it were detected in a
panel of six cell lines, including DOHH2, OCI-LY1,
OCI-LY8, Toledo, Raji, and Namalwa. From the results
obtained at the cell-line level as well as in clinical tis-
sues, it can be seen that CNV was a common event
in almost all components of the PI3K/AKT signaling
pathway.
Using TMA, we found that of all the members sub-
jected to IHC, p110α, p110β, p110γ, and p110δ proteinexpression rates were 80%, 81.6%, 81.6%, and 81.6%, re-
spectively. This was similar to the findings of Meadows’s
findings in Hodgkin Lymphoma (HL) where they showed
that the positive expression of p110α, p110β, p110γ, and
p110δ was 97.2%, 29.2%, 54.4% and 80.6%, respectively
[23]. The expression of p110α has been reported to be
an independent factor for predicting decreased OS for
patients with ovarian cancers [17] and gastric cancers
[19], although there are no related reports with respect
to lymphoma. Protein expressions of p110α, p110β,
Figure 3 Protein expression of p110α, p110β, p110γ, p110δ, and pAKT correlated with patient survival in DLBCL. It showed that strong
positive expression of p110α, p110β, p110γ, and p110δ were associated with decreased survival. Moderate and strong positive expression of pAKT
showed correlation with decreased survive, however, there is no statistical significance. A. Patients grouped by strong positive expression of
p110α(P = 0.022). B. Patients grouped by strong positive expression of p110β(P =0.015). C. Patients grouped by strong positive expression of
p110γ(P =0.015). D. Patients grouped by strong positive expression of p110δ(P =0.008). E. Patients grouped by moderate and strong positive of
pAKT(P =0.165).
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poor survival.
With regard to AKT, whose active form is phosphory-
lated AKT (pAKT). It has been reported that p110α
amplification was closely associated with pAKT expres-
sion. In the study, CNV of PIK3CA was highly associ-
ated with aberrant p110α protein expression, which
subsequently associated with pAKT, indicating p110α
was main isoform for activation of the downstream core
protein AKT in DLBCL. PAKT has been extensively re-
ported to be associated with poor prognosis in different
types of cancer [15,24-26]. Expression of pAKT has
shown a trend towards decreased 5-year survival for pa-
tients with DLBCL (P = 0.05) [5], while another study
showed that high pAKT expression had decreased OS
(P = 0.036) [27]. In our research, high pAKT expression
was associated with poor survival, although statistical
significance was not reached. Due to limited number of
cases in the study, large cohort study is required to
further investigate their relationship and validate our
findings.Conclusions
In summary, CNVs of PI3K and AKT subunits were a
common event in the DLBCL. CNV of PIK3CA is highly
associated with aberrant p110α protein expression and
subsequent activation of PI3K/AKT pathway. CNVs of
PIK3CA and PIK3CB, and aberrant protein expression
of p110 isoforms are of great important value for pre-
dicting inferior prognosis in DLBCL. Frequent CNVs of
PI3K/AKT subunits may play an important role in the
tumorigenesis of DLBCL.
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